View Alert


Originator: DHSC & NHS England and Improvement: Supply disruption alert

Issue date: 08-Oct-2020 16:08:31

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Specialists Trusts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Special Health Authorities
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Mental Health & Learning Disabilities
  • Acute Trusts
  • Community Trusts
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • DHSC Supply Disruption - Medicines
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: Lithium carbonate (Priadel) 200mg and 400mg modified release tablets - Supply Disruption Update

Broadcast content:

The information in this alert provides an update to SDA/2020/012 issued on 21st August 2020.

Essential Pharma has informed the Department of Health and Social Care (DHSC) of its decision to reverse the discontinuation of Priadel 200mg and 400mg tablets from the UK market with immediate effect, whilst facilitating pricing discussions. As such the discontinuation notice issued to DHSC earlier this year has been withdrawn.

In light of this, clinicians across all healthcare settings are advised that there is no longer a need to implement system wide switching of patients from Priadel tablets to an alternative lithium carbonate preparation until further notice.

Essential Pharma has confirmed supplies of Priadel 200mg and 400mg tablets are sufficient to meet current UK demand and is working to ensure further stocks are available to maintain supply after April 2021.

All Patients who require lithium treatment should now continue to be managed in line with usual clinical practice underpinned by the relevant NICE guidance.

Although DHSC cannot confirm a discontinuation will not take place in future, it is important to note that under the Health Service Products (Provision and Disclosure of Information) Regulations 2018, marketing authorisation holders must provide the DHSC a minimum of six months’ notice of an intention to discontinue a product from the UK market.

The attached alert contains further information.

Please note that no response is required via the CAS website to this alert.



Additional information: NHS England and NHS Improvement Regional offices: please cascade this alert to community pharmacy.

Alert reference: SDA/2020/012(U)

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency